Skip to main content

Table 4 Univariate and multivariate analysis with respect to progression free survival in 61 triple-negative and 45 HER2-positive breast cancers

From: Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Parameters Univariate analysis Multivariate analysis
Hazard ratio 95% CI p value Hazard ratio 95% CI p value
TNBC (n = 61)
 Lymph node status
  Positive vs negative 0.942 0.203–4.359 0.939 1.303 0.216–7.854 0.773
 Ki67
  ≤ 14% vs > 14% 0.739 0.216–2.526 0.630 1.866 0.395–8.817 0.431
 Pathological response
  pCR vs non-pCR 0.234 0.050–1.084 0.063 0.722 0.103–5.057 0.743
 PD-1
  Positive vs negative 3.318 1.011–10.891 0.048 0.869 0.177–4.265 0.863
 PD-L1
  Positive vs negative 8.375 1.807–38.812 0.007 9.479 1.092–82.320 0.041
HER2+BC (n = 45)
 Lymph node status
  Positive vs negative 0.603 0.318–1.145 0.122 0.641 0.318–1.294 0.215
 Ki67
  ≤ 14% vs > 14% 0.714 0.385–1.326 0.286 0.730 0.371–1.436 0.362
 Pathological response
  pCR vs non-pCR 0.670 0.358–1.254 0.210 0.912 0.428–1.944 0.811
 PD-1
  Positive vs negative 1.990 0.585–6.766 0.271 1.333 0.114–15.527 0.819
 PD-L1
  Positive vs negative 1.934 0.651–5.738 0.235 1.568 0.187–13.175 0.679
  1. TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, CI confidence interval, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand